Elicio Therapeutics, Inc. (ELTX) is a Biotechnology company in the Healthcare sector, currently trading at $11.78. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 2 out of 7 criteria passed.
Analyst consensus target is ELTX = $17 (+44.3% upside).
Valuation: ELTX trades at a trailing Price-to-Earnings (P/E) of -3.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.61.
Net income is $40M (loss), growing at -16.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $15M against $2M equity (Debt-to-Equity (D/E) ratio 8.87, leveraged). Current ratio is 2.38 (strong liquidity). Debt-to-assets is 56.1%. Total assets: $26M.
Analyst outlook: 1 / 2 analysts rate ELTX as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 96/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 33/100 (Fail), Moat 28/100 (Fail), Future 64/100 (Pass), Income ?/100 (Fail).
